The $150 Million Patent

Amarin (Nasdaq: AMRN  ) was up as much as 17% after the U.S. Patent and Trademark Office posted a "Reasons for Allowance" for multiple patents the biotech has sought to cover its lipid drug, AMR101.

That's patent-speak for "going to be approved." And given that AMR101 is Amarin's only drug and on the verge of approval next month, it's understandable that the patent would add $150 million to the market cap of the company. Keeping generic copy cats at bay until 2030 is certainly worth something.

ARM101 won't be completely without generic competition during that time, though. The drug is a fish oil product similar to GlaxoSmithKline's (NYSE: GSK  ) Lovaza, albeit in a more purified form. Lovaza is expected to see generic competition from Apotex starting in 2015, which Amarin will have to compete with. Generics from Teva Pharmaceuticals (NYSE: TEVA  ) and Par Pharmaceutical (NYSE: PRX  ) won't come until later because they lost their court case.

With the patent uncertainty nearly out of the way, investors can turn to the issues of who will market AMR101 once it's approved. There's speculation, like there is for VIVUS (Nasdaq: VVUS  ) , that the company will find an acquirer or a partner to launch the drug. For both companies, that seems like a prudent move. Cardiovascular and obesity are large markets that require many sales reps because the drugs are often prescribed by primary care physicians.

The patents, assuming everything goes as planned, should increase Amarin's attractiveness as an acquisition target. Considering the outstanding data to date, it looks like the intellectual property estate has been one of the main issues holding back the sale of the company. Pharma companies certainly don't need any more patent headaches than they already have.

Investors should keep in mind that a sale isn't a sure thing. Potential acquirers could still be worried about the enforceability of the patents. It's still very possible that Amarin ends up with a licensing deal, keeping the risk that the patents get overturned by the court on the shoulders of Amarin.

David Gardner and his team at Rule Breakers aren't counting on an acquisition to get solid returns from one of their recent health-care picks. Find out what it is and why they like it in the Fool's free report, "Discover the Next Rule-Breaking Multibagger."

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 01, 2012, at 3:26 PM, vic929 wrote:

    You didn't quite do all your homework before writing this article. The genrics for Lovaza as well as Lovaza are of no competition to AMR101. The reason is AMR101 lowered small LDL particle count by 25.6% and lowered trigs by 33%. ..... all without raising the total amount of LDL cholesterol. Lovaza raises total LDL levels so they are completely different.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1928701, ~/Articles/ArticleHandler.aspx, 11/23/2014 5:55:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement